Skip to main content
Equibles
SHPH logo

SHPH · Shuttle Pharmaceuticals Holdings, Inc. · Metrics

Track SHPH — free

Use SHPH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SHPH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.42 -0.11 (-3.12%)
Rebalance outlook locked
Going-concern doubt — flagged May 15, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our ability to continue as a going concern is dependent upon our ability to continue to successfully raise additional equity or debt financing to allow us to fund ongoing operations, and commercialize, fund milestone and contingent payments due under the APA, and market our Molecule.ai platform in order to generate revenues. These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements contained in the report are issued.”
View the 10-Q filed May 15, 2026
Market Cap
$2.05M
Shares
585,129

SHPH metrics

41 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.53
Market cap
$2.05M

Price action

20 metrics
Price change (1W)
+0.3%
Price change (30D)
-18.8%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
156.6%
Annualized volatility (3M)
—
Beta
—
RSI (14D)
46.6
Price vs SMA 50
-1.8%
Price vs SMA 200
—
Avg volume (3M)
2.15M
Relative volume
0.0
Average dollar volume
$8.25M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
585,129

Valuation

12 metrics
P / E (TTM)
35.0
Trailing earnings · reciprocal yield 2.9%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.6
reciprocal yield 163.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-528.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-05-14

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$11.18M
Net income (TTM)
−$10.82M
Trailing 12 months
Diluted EPS (TTM)
$0.10
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$11.14

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1,151.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-323.4%
Return on assets
-91.6%
Debt / equity
—
Current ratio
0.3
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.09M
Total assets
$11.81M
Total debt
$91,021

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$9.37M
Capital expenditures (TTM)
—
R&D (TTM)
$2.75M
SG&A (TTM)
—
Stock compensation (TTM)
$430,939
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
5
13F filer change QoQ
-3
Institutional ownership
17.8%

Short interest

3 metrics
Short interest
6.7%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
43 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$323,067
Insider-sentiment score
37 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1757499 CUSIP 825693500 13F (30d) 3 filings 3 filers Visit website Investor relations